Pharmacyclics Submits NDA for ibrutinib Against MCL and SLL

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib.

The NDA is for ibrutinib as a treatment for patients with relapsed/refractory mantle cell lymphoma (MCL) or relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

The company submitted the NDA supported by data from Phase II studies in patients with both B-cell non-Hodgkin's lymphomas listed above. The company is seeking priority review.

Earlier this year the FDA gave Breakthrough Therapy Designation for ibrutinib as a monotherapy for the treatment of patients with relapsed/refractory MCL, and Breakthrough Therapy Designation for the treatment of patients with CLL/SLL with deletion of the short arm of chromosome 17 (del 17p).

Said Dr. Urte Gayko, Senior Vice President of Global Regulatory Affairs, Pharmacyclics,

We are very excited having achieved this major milestone. This first NDA for ibrutinib was made possible in record time because of the continuous support and consultations we received from the FDA. We look forward to continuing to work with the FDA as they review the application for ibrutinib through the new Breakthrough Therapy Designation process.

For up-to-date information on this study please visit the PCYC-04753 page at ClinicalTrials.gov

Source: Pharmacyclics

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Sitemap